FDA Biologics Center Seeking To Address Device Industry Concerns – Zoon
This article was originally published in The Gray Sheet
Executive Summary
Responsibility for the regulation of products related to blood safety should remain with FDA's Center for Biologics Evaluation & Research, according to CBER Director Kathryn Zoon